Abstract
BACKGROUND: The pulmonary vasculature is essential for gas exchange and impacts both pulmonary and cardiac function. However, it is difficult to assess and its characteristics in the general population are unknown. We measured pulmonary blood volume (PBV) noninvasively using contrast enhanced, dual-energy computed tomography to evaluate its relationship to age and symptoms among older adults in the community.
METHODS: The MESA (Multi-Ethnic Study of Atherosclerosis) is an ongoing community-based, multicenter cohort. All participants attending the most recent MESA exam were selected for contrast enhanced dual-energy computed tomography except those with estimated glomerular filtration rate <60 mL/min per 1.73 m 2. PBV was calculated by material decomposition of dual-energy computed tomography images. Multivariable models included age, sex, race/ethnicity, education, height, weight, smoking status, pack-years, and scanner model.
RESULTS: The mean age of the 727 participants was 71 (range 59-94) years, and 55% were male. The race/ethnicity distribution was 41% White, 29% Black, 17% Hispanic, and 13% Asian. The mean±SD PBV in the youngest age quintile was 547±180 versus 433±194 mL in the oldest quintile ( P<0.001), with an approximately linear decrement of 50 mL per 10 years of age ([95% CI, 32-67]; P<0.001). Findings were similar with multivariable adjustment. Lower PBV was associated independently with a greater dyspnea after a 6-minute walk ( P=0.04) and greater composite dyspnea symptom scores ( P=0.02). Greater PBV was also associated with greater height, weight, lung volume, Hispanic race/ethnicity, and nonsmoking history.
CONCLUSIONS: Pulmonary blood volume was substantially lower with advanced age and was associated independently with greater symptoms scores in the elderly.
Original language | English (US) |
---|---|
Pages (from-to) | E014380 |
Journal | Circulation: Cardiovascular Imaging |
Volume | 15 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2022 |
Bibliographical note
Funding Information:Dr Hoffman is a founder and shareholder of VIDA Diagnostics, which makes the software used for secondary (percent emphysema) but not primary (PBV) measures in this article. Dr Kaczka acknowledges grant support from the US Department of Defense and ZOLL Medical Corporation, for work unrelated to this study, is as a paid consultant to Lungpacer Medical, Inc, is a co-founder and shareholder of OscillaVent, Inc and is listed as a co-inventor on United States and European patents related to multi-frequency oscillatory ventilation. Dr Guo is a shareholder of VIDA Diagnostics. Unrelated to this work, Dr Michos reports advisory boards for AstraZeneca, Amarin, Bayer, Esperion, Novartis, and Novo Nordisk.
Funding Information:
This publication was supported by NIH/National Heart, Lung, and Blood Institute R01-HL077612, R01-HL093081, R01-HL130506, N01-HC-95159 through N01-HC-95165, N01-HC-95169 and the National Center for Advancing Translational Sciences (Grant Number UL1 TR000040).
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
Keywords
- aging
- blood volume
- physiology
- pulmonary circulation
- tomography
- Lung/diagnostic imaging
- Tomography, X-Ray Computed/methods
- Humans
- Middle Aged
- Male
- Dyspnea
- Aged, 80 and over
- Blood Volume
- Female
- Aged
- Cohort Studies
PubMed: MeSH publication types
- Multicenter Study
- Journal Article
- Research Support, N.I.H., Extramural